2.57
-0.15(-5.51%)
Currency In USD
| Previous Close | 2.72 |
| Open | 2.68 |
| Day High | 2.73 |
| Day Low | 2.56 |
| 52-Week High | 3.05 |
| 52-Week Low | 0.86 |
| Volume | 213,229 |
| Average Volume | 579,120 |
| Market Cap | 155.67M |
| PE | -1.16 |
| EPS | -2.21 |
| Moving Average 50 Days | 2.14 |
| Moving Average 200 Days | 1.64 |
| Change | -0.15 |
If you invested $1000 in Acumen Pharmaceuticals, Inc. (ABOS) since IPO date, it would be worth $127.86 as of February 21, 2026 at a share price of $2.57. Whereas If you bought $1000 worth of Acumen Pharmaceuticals, Inc. (ABOS) shares 3 years ago, it would be worth $484.91 as of February 21, 2026 at a share price of $2.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire Inc.
Dec 02, 2025 1:00 PM GMT
NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheime
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire Inc.
Nov 18, 2025 1:00 PM GMT
NEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheime
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
NEWTON, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheime